Your browser doesn't support javascript.
loading
Epicardial adipose tissue measured from analysis of adipose tissue area using chest CT imaging is the best potential predictor of COVID-19 severity.
Fukushima, Takahiro; Maetani, Tomoki; Chubachi, Shotaro; Tanabe, Naoya; Asakura, Takanori; Namkoong, Ho; Tanaka, Hiromu; Shimada, Takashi; Azekawa, Shuhei; Otake, Shiro; Nakagawara, Kensuke; Watase, Mayuko; Shiraishi, Yusuke; Terai, Hideki; Sasaki, Mamoru; Ueda, Soichiro; Kato, Yukari; Harada, Norihiro; Suzuki, Shoji; Yoshida, Shuichi; Tateno, Hiroki; Yamada, Yoshitake; Jinzaki, Masahiro; Hirai, Toyohiro; Okada, Yukinori; Koike, Ryuji; Ishii, Makoto; Kimura, Akinori; Imoto, Seiya; Miyano, Satoru; Ogawa, Seishi; Kanai, Takanori; Fukunaga, Koichi.
Afiliação
  • Fukushima T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Maetani T; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Chubachi S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: bachibachi472000@z6.keio.jp.
  • Tanabe N; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: ntana@kuhp.kyoto-u.ac.jp.
  • Asakura T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan; Department of Respiratory Medicine, Kitasato University, Kitasato In
  • Namkoong H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Tanaka H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Shimada T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Azekawa S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Otake S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Nakagawara K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Watase M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Shiraishi Y; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Terai H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Sasaki M; Internal Medicine, JCHO (Japan Community Health care Organization) Saitama Medical Center, Saitama, Japan.
  • Ueda S; Internal Medicine, JCHO (Japan Community Health care Organization) Saitama Medical Center, Saitama, Japan.
  • Kato Y; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Harada N; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Suzuki S; Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Yoshida S; Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Tateno H; Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Yamada Y; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
  • Jinzaki M; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
  • Hirai T; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Okada Y; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
  • Koike R; Health Science Research and Development Center, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kimura A; Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
  • Imoto S; Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Miyano S; M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ogawa S; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
  • Kanai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Metabolism ; 150: 155715, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37918794
ABSTRACT

BACKGROUND:

Computed tomography (CT) imaging is widely used for diagnosing and determining the severity of coronavirus disease 2019 (COVID-19). Chest CT imaging can be used to calculate the epicardial adipose tissue (EAT) and upper abdominal visceral adipose tissue (Abd-VAT) areas. The EAT is the main source of inflammatory cytokines involved in chest inflammatory diseases; thus, the EAT area might be a more useful severity predictor than the Abd-VAT area for COVID-19. However, to the best of our knowledge, there are no large-scale reports that sufficiently consider this issue. In addition, there are no reports on the characteristics of patients with normal body mass index (BMI) and high adipose tissue.

AIM:

The purpose of this study was to analyze whether the EAT area, among various adipose tissues, was the most associated factor with COVID-19 severity. Using a multicenter COVID-19 patient database, we analyzed the associations of chest subcutaneous, chest visceral, abdominal subcutaneous, and Abd-VAT areas with COVID-19 outcomes. In addition, the clinical significance of central obesity, commonly disregarded by BMI, was examined.

METHODS:

This retrospective cohort study evaluated patients with COVID-19 aged ≥18 years In Japan. Data including from chest CT images collected between February 2020 and October 2022 in four hospitals of the Japan COVID-19 Task Force were analyzed. Patient characteristics and COVID-19 severity were compared according to the adipose tissue areas (chest and abdominal subcutaneous adipose tissue [Chest-SAT and Abd-SAT], EAT, and Abd-VAT) calculated from chest CT images.

RESULTS:

We included 1077 patients in the analysis. Patients with risk factors of severe COVID-19 such as old age, male sex, and comorbidities had significantly higher areas of EAT and Abd-VAT. High EAT area but not high Abd-VAT area was significantly associated with COVID-19 severity (adjusted odds ratio (aOR) 2.66, 95 % confidence interval [CI] 1.19-5.93). There was no strong correlation between BMI and VAT. Patients with high VAT area accounted for 40.7 % of the non-obesity population (BMI < 25 kg/m2). High EAT area was also significantly associated with COVID-19 severity in the non-obesity population (aOR 2.50, 95 % CI 1.17-5.34).

CONCLUSIONS:

Our study indicated that VAT is significantly associated with COVID-19 severity and that EAT is the best potential predictor for risk stratification in COVID-19 among adipose tissue areas. Body composition assessment using EAT is an appropriate marker for identifying obesity patients overlooked by BMI. Considering the next pandemic of the global health crisis, our findings open new avenues for implementing appropriate body composition assessments based on CT imaging.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Adolescent / Adult / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Adolescent / Adult / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article